Pfizer (PFE) Net Cash Flow (2009 - 2026)

Pfizer (PFE) has reported Net Cash Flow for 18 consecutive years, with -$722.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Cash Flow fell 517.34% year-over-year to -$722.0 million in Q2 2026; TTM through Jun 2026 was -$684.0 million, a 15.87% increase from a year earlier, with the FY2025 full-year figure at $49.0 million, up 102.81% from the prior year.
• Net Cash Flow was -$722.0 million for Q2 2026 at Pfizer, down from $544.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $1.8 billion in Q2 2023 and troughed at -$2.1 billion in Q1 2024.
• A 5-year average of -$126.4 million and a median of -$14.5 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 6725.0% in 2022 and tumbled 517.34% in 2026, its largest moves.
• Over 5 years, Net Cash Flow stood at -$617.0 million in 2022, then jumped by 49.11% to -$314.0 million in 2023, then tumbled by 450.32% to -$1.7 billion in 2024, then soared by 88.31% to -$202.0 million in 2025, then plunged by 257.43% to -$722.0 million in 2026.
• The last three Net Cash Flow figures came in at -$722.0 million (Q2 2026), $544.0 million (Q1 2026), and -$202.0 million (Q4 2025), per Business Quant data.